• Selective β1 Blockade Spares Hematopoietic Regeneration Afte

  2026-07-26

  This study demonstrates that nonselective β-adrenergic blockers impair hematopoietic recovery following hematopoietic cell transplantation (HCT) in mice and humans, whereas β1-selective agents like Metoprolol Tartrate do not. The findings clarify the importance of adrenergic receptor selectivity in post-transplant protocols and guide the rational design of research and clinical strategies.

• Cell Cycle Assay Kit (K2263): Precision Analysis of Cell Cyc

  2026-07-25

  The Cell Cycle Assay Kit enables quantitative analysis of cell cycle phases G0/G1, S, and G2/M via propidium iodide staining and flow cytometry. This method supports accurate detection of apoptotic cells by sub-G1 peak analysis and is widely applied in cancer research cell proliferation studies.

• Neomycin Sulfate: Applied Protocols for RNA/DNA & Ion Channe

  2026-07-24

  Neomycin sulfate stands out as an aminoglycoside antibiotic that enables highly reproducible molecular assays targeting RNA/DNA structures and ion channel functions. This article delivers actionable workflows, troubleshooting guidance, and practical integration of recent immunology-microbiome findings to drive advanced molecular biology research.

• Ceftolozane/Tazobactam: Innovations for Resistant Gram-Negat

  2026-07-24

  The reference study presents ceftolozane/tazobactam as a novel cephalosporin/beta-lactamase inhibitor combination with potent activity against multidrug-resistant gram-negative bacteria, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. Its distinctive pharmacodynamics and clinical efficacy in complicated intraabdominal and urinary tract infections mark a significant advance in antibacterial therapy.

• Endogenous H2S Deficiency Drives Lipotoxicity in Diabetic He

  2026-07-23

  This study uncovers a mechanism linking deficient endogenous hydrogen sulfide (H2S) production with enhanced endoplasmic reticulum (ER) stress and lipotoxicity in diabetic cardiomyopathy. The findings highlight how restoring H2S signaling may mitigate cardiac damage, with methodological implications for quantifying DNA-level changes in cardiac models.

• A40926: Dalbavancin Precursor for Advanced Antibacterial Res

  2026-07-23

  A40926, a potent dalbavancin precursor, delivers robust inhibition of Gram-positive and multidrug-resistant pathogens, outperforming legacy antibiotics in both in vitro and in vivo assays. This guide decodes advanced production, assay workflows, and troubleshooting strategies, grounded in the latest bioprocessing and application research.

• ATS-9R Enables ATM-Targeted Gene Silencing in GDM Models

  2026-07-22

  This study demonstrates that targeted gene silencing of CCL2 in adipose tissue macrophages (ATMs) using the ATS-9R/siCcl2 complex effectively reduces local inflammation and improves insulin resistance in gestational diabetes mellitus (GDM) models. The findings highlight a precise, non-viral gene delivery approach that holds translational promise for metabolic disease research.

• Partial BACE1 Inhibition Preserves Synaptic Function in AD M

  2026-07-22

  Satir et al. (2020) demonstrate that partial inhibition of BACE1, resulting in up to a 50% reduction of amyloid beta production, does not impair synaptic transmission in cultured neurons. This finding refines Alzheimer’s disease research strategies by supporting moderate BACE inhibitor dosing to balance efficacy with synaptic safety.

• DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution

  2026-07-21

  DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use, blue-fluorescent DNA stain for reliable nuclear visualization in fixed or membrane-compromised cells. It is well-suited for fluorescence microscopy and flow cytometry but should not be used for live-cell imaging due to limited cell permeability.

• A40926: Strategic Leverage in Translational Antibiotic Innov

  2026-07-21

  This thought-leadership article examines A40926 as a critical tool in translational research against Gram-positive and multidrug-resistant pathogens. It bridges mechanistic insights, experimental strategies, and biosynthetic engineering with practical guidance for researchers, offering context-driven recommendations and highlighting the unique value of A40926 as both a research benchmark and a springboard for next-generation antibiotics.

• PR-619: Practical Guidance for Deubiquitylating Enzyme Inhib

  2026-07-20

  PR-619 is a cell-permeable, reversible inhibitor targeting a broad range of cysteine-dependent deubiquitinating enzymes (DUBs), facilitating the study of ubiquitination dynamics in cell-based assays without direct proteasomal inhibition. It is best suited for workflows investigating the accumulation of ubiquitinated proteins or dissecting autophagy and protein degradation pathways, but requires careful solubilization and dosing strategies to avoid off-target cytotoxicity.

• CCK-8 Modulates Opioid-Dependent Anxiety in Morphine Withdra

  2026-07-20

  This study identifies cholecystokinin octapeptide (CCK-8) as a regulator of anxiety-like behavior in morphine-withdrawal rats, revealing a novel endogenous opioid-dependent anxiolytic mechanism mediated via CCK1 receptors. The findings highlight new neurobiological targets for opioid addiction and withdrawal research, with implications for the development of therapies addressing negative affect during abstinence.

• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-07-19

  This study demonstrates that the protein disulfide isomerase (PDI) inhibitor LTI6426 significantly enhances the anti-tumor activity of panobinostat (Pano) in preclinical multiple myeloma models. The findings support a new combination approach that may permit lower, better-tolerated doses of panobinostat, with implications for optimizing epigenetic therapies in resistant disease.

• Targeting eIF4F, AKT1, and EZH2 in BRAFV600E Melanoma: Syner

  2026-07-18

  This study demonstrates that combinatorial inhibition of the eIF4F complex, AKT1, and EZH2 overcomes resistance to targeted therapies in BRAFV600E mutant melanoma cells. The findings highlight a coordinated signaling network underpinning drug resistance and suggest that dual or triple inhibitor strategies may significantly enhance anticancer efficacy in refractory melanoma models.

• Structural Insights into Nipah Virus Polymerase Complex Func

  2026-07-17

  The reference study elucidates the high-resolution structure of the Nipah virus L-P polymerase complex, revealing key mechanistic details of viral RNA synthesis and protein interactions. These findings provide a critical foundation for rational antiviral drug design targeting the replication machinery of henipaviruses and related RNA viruses.

450 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page